Eli Lilly is suing four telemedicine companies selling compounded versions of its blockbuster obesity drug Zepbound and its ...

Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...

The drug company Eli Lilly is suing four telehealth companies for allegedly selling copies made by compounding pharmacies of ...

The weight loss drug market could grow to $500 billion over the next decade. Eli Lilly's next-generation products look promising, while competitors have stumbled in clinical trials. Investors are ...

Eli Lilly's oral GLP-1 medicine aced a phase 3 study. It should become a new growth driver for the company. There are other reasons to invest in the pharmaceutical leader. Zepbound's prospects ...

Eli Lilly is suing four telehealth companies that prescribe compounded versions of the pharmaceutical company's weight loss medications. Lilly filed four lawsuits on Wednesday claiming telehealth ...

Given the potential opportunities in the sector, should investors buy Eli Lilly stock? Here's where the company and its stock stand now. The GLP-1 agonist opportunity is gearing up for its next ...

April 23 (UPI) --Eli Lilly Wednesday filed lawsuits against four telehealth companies alleging they are deceiving consumers by selling compounds of slightly-different versions of Lilly drugs.

The most recent trading session ended with Eli Lilly (LLY) standing at $827.54 ... the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and ...

And Lilly just took a major step in the right direction. Did Eli Lilly just say checkmate to Novo Nordisk? Let's find out. So, first a quick bit about how this class of drugs works. Novo Nordisk's ...